Overview

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving radiation therapy after chemotherapy may be an effective treatment for Hodgkin's disease. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating children who have previously untreated stage II, stage III, or stage IV Hodgkin's disease.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Bleomycin
Cyclophosphamide
Dacarbazine
Doxorubicin
Etoposide
Etoposide phosphate
Lenograstim
Liposomal doxorubicin
Prednisone
Procarbazine
Vinblastine
Vincristine
Criteria
DISEASE CHARACTERISTICS: Histologically proven, previously untreated Hodgkin's disease
Stage IV OR Stage II or stage III with B symptoms (at least 1 of the following: unexplained
weight loss greater than 10%, unexplained recurrent fever greater than 39 degrees C, or
drenching night sweats) AND bulk disease (defined as a mediastinal mass greater than 1/3 of
mediastinal thoracic diameter and/or nodal aggregate greater than 10.0 cm) The following
cellular types are eligible: Mixed cellularity, not otherwise specified (NOS) Lymphocytic
depletion, NOS Lymphocytic depletion, diffuse fibrosis Lymphocytic depletion, reticular
Lymphocytic predominance, NOS Lymphocytic predominance, diffuse Lymphocytic predominance,
nodular Hodgkin's paragranuloma Hodgkin's granuloma Hodgkin's sarcoma Nodular sclerosis,
NOS Nodular sclerosis, cellular phase Nodular sclerosis, lymphocytic predominance Nodular
sclerosis, mixed cellularity Nodular sclerosis, lymphocytic depletion Hodgkin's disease,
NOS Must begin protocol therapy within 42 days of biopsy and 7 days of completion of
staging

PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Life
expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
specified Other: Not pregnant or nursing Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: No prior treatment for Hodgkin's disease